On May 4, 2026, Perspective Therapeutics posted a presentation containing preliminary cash balance estimates for Q1 2026 and clinical data updates for its VMT-⍺-NET program.
Key takeaways
The Company disclosed estimated cash, cash equivalents and short-term investments as of March 31, 2026, which are preliminary and unaudited.
Independent auditors WithumSmith+Brown, PC have not reviewed or compiled the preliminary financial data and express no opinion on it.
VMT-⍺-NET Phase 1/2a data showed durable disease control across all doses in the AACR 2026 analysis.
The presentation highlights a compassionate use program for VMT-⍺-NET in Meningioma, suggesting potential expansion opportunities.
The Company emphasized its integrated isotope production and direct-to-hospital delivery infrastructure for 212Pb-based therapies.